81,157 Shares in CG Oncology, Inc. $CGON Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in CG Oncology, Inc. (NASDAQ:CGON) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 81,157 shares of the company’s stock, valued at approximately $5,766,000. The Manufacturers Life Insurance Company owned about 0.09% of CG Oncology as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of CGON. Fiduciary Financial Advisors bought a new position in shares of CG Oncology during the second quarter worth about $28,000. NFSG Corp acquired a new position in CG Oncology during the 1st quarter valued at about $34,000. Comerica Bank boosted its stake in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Fifth Third Bancorp bought a new position in CG Oncology in the 1st quarter worth about $74,000. Finally, KBC Group NV bought a new position in CG Oncology in the 1st quarter worth about $78,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Friday, July 17th. Wedbush raised their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen downgraded CG Oncology from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Royal Bank Of Canada reduced their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research note on Wednesday, July 29th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $83.18.

CG Oncology Trading Up 1.1%

Shares of CG Oncology stock opened at $75.16 on Tuesday. CG Oncology, Inc. has a 52 week low of $26.22 and a 52 week high of $80.97. The company’s 50-day moving average price is $73.22 and its two-hundred day moving average price is $66.72. The stock has a market cap of $6.66 billion, a PE ratio of -27.94 and a beta of 0.23.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%. On average, equities analysts predict that CG Oncology, Inc. will post -3.27 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director James Mulay sold 24,165 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the sale, the director owned 24,165 shares in the company, valued at approximately $1,816,241.40. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brian Guan-Chyun Liu acquired 371,085 shares of the stock in a transaction on Thursday, June 25th. The shares were purchased at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the transaction, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 38,129 shares of company stock worth $2,738,357. Company insiders own 4.80% of the company’s stock.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.